CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 506 enrolled
Drug / intervention
Fimasartan +1 moredrug
Likely dose
Fimasartan 120mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00922480
NCT00922480Phase 3Completed

A Randomized, Double-blind, Losartan-controlled, Parallel Group Comparison Dose Titration Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan 60mg~120mg in Patients With Mild to Moderate Essential Hypertension

Boryung Pharmaceutical Co., Ltd·interventional·Posted Jun 17, 2009·Updated Apr 10, 2018

In Brief

A Phase 3 clinical trial evaluating Fimasartan and Losartan (Control) for Hypertension. Completed, enrolled 506 participants.

Detailed Summary

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) 60 mg\~120 mg in patients with mild to moderate essential hypertension.

Study Details

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 17, 2009
Enrollment StartDec 1, 2008
Primary CompletionJul 1, 2009
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.0 years ago

Interventions

Fimasartandrug

Fimasartan 60 \~ 120mg/po take one tablets once a day

Losartan (Control)drug

Losartan 50 mg \~ 100 mg/po, take one tablets once a day